Related Experiment Video
Updated: May 10, 2026
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Medical management of critical limb ischaemia: where do we stand today?
1Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Insights
Critical limb ischaemia (CLI) management focuses on pain relief, ulcer healing, and preventing limb loss. Medical treatments like antiplatelet agents are recommended, while others lack sufficient evidence for routine use.
Area of Science:
- Vascular Medicine
- Cardiovascular Disease Management
Background:
- Critical limb ischaemia (CLI) is a severe manifestation of peripheral arterial disease (PAD).
- CLI significantly impairs quality of life, leading to pain, potential limb loss, and increased cardiovascular mortality.
- Effective management aims to alleviate symptoms, promote healing, preserve limbs, and enhance survival.
Purpose of the Study:
- To review current evidence on the medical management of critical limb ischaemia.
- To assess the efficacy of various therapeutic strategies for CLI.
- To identify optimal approaches for improving outcomes in CLI patients.
Main Methods:
- Systematic review of current evidence on medical management for CLI.
- Analysis of studies on cardiovascular risk factor modification.
- Evaluation of pharmacological and investigational therapies for limb salvage and symptom relief.
Main Results:
- Cardiovascular risk factor control (smoking cessation, hypertension, hyperlipidemia, diabetes) is crucial for reducing mortality.
- Antiplatelet agents (aspirin, clopidogrel) are recommended for preventing cardiovascular events and arterial occlusion.
- Prostanoids show potential for rest pain and ulcer healing, with iloprost reducing amputation risk; evidence for naftidrofuryl, cilostazol, pentoxifylline, and hyperbaric oxygen is insufficient.
- Angiogenic growth factors and stem cell therapies show early promise but require further large-scale trials.
- Thrombolysis is an option for acute limb ischaemia, with endovascular techniques expected to play a larger future role.
Conclusions:
- Comprehensive management of CLI involves aggressive cardiovascular risk factor modification and antiplatelet therapy.
- While some treatments like prostanoids offer limb-specific benefits, many pharmacological options lack robust evidence.
- Emerging therapies like growth factors and stem cells warrant further investigation, alongside the growing importance of endovascular interventions.
Abstract:
Critical limb ischaemia (CLI) is a severe form of peripheral arterial disease (PAD). CLI often causes disabling symptoms of pain and can lead to loss of the affected limb. It is also associated with increased risk of myocardial infarction, stroke and death from cardiovascular disease. The aims of management in patients with CLI are to relieve ischaemic pain, heal ulcers, prevent limb loss, improve function and quality of life and prolong survival. Here, current evidence regarding the medical management of CLI is reviewed. Cardiovascular risk factors should be assessed in all patients with CLI; smoking cessation and treatment of hypertension, hyperlipidaemia and diabetes all reduce the mortality rate in those with PAD. Antiplatelet agents (either aspirin or clopidogrel) are recommended to reduce both the incidence of cardiovascular events and risk of arterial occlusion. By contrast, routine use of anticoagulation (either warfarin or heparin) is not recommended. Treatment of the limbs themselves is often more challenging. Prostanoids may have some efficacy for treating rest pain and for ulcer healing, and iloprost shows favourable results in reducing the risk of major amputations, but long-term follow-up data regarding disease progression are lacking. There is insufficient evidence to support the use of naftidrofuryl or cilostazol, and pentoxifylline is not beneficial. Furthermore, there is no evidence of proven benefit of hyperbaric oxygen. A number of angiogenic growth factors have been studied in Phase I studies and randomized controlled trials (RCTs). They appear to be safe, but efficacy results have been mixed. Treatment with stem cells also shows some potential from early trials, but further larger RCTs are needed to demonstrate clear benefit. Thrombolysis may be an alternative for patients who develop acute limb ischaemia and are unsuitable for surgical intervention. However, newer endovascular techniques are likely to have a greater role in the future.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Peripheral Artery Disease IV: Nursing Management
01:26Atherosclerosis III: Management
01:26Angina IV: Management
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:23Atherosclerosis IV: Nursing Management